CA3070453A1 - S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same - Google Patents

S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same Download PDF

Info

Publication number
CA3070453A1
CA3070453A1 CA3070453A CA3070453A CA3070453A1 CA 3070453 A1 CA3070453 A1 CA 3070453A1 CA 3070453 A CA3070453 A CA 3070453A CA 3070453 A CA3070453 A CA 3070453A CA 3070453 A1 CA3070453 A1 CA 3070453A1
Authority
CA
Canada
Prior art keywords
subject
composition
compound
alzheimer
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070453A
Other languages
English (en)
French (fr)
Inventor
Eric Verdin
John C. Newman
Original Assignee
J David Gladstone Institutes
Buck Institute for Research on Aging
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J David Gladstone Institutes, Buck Institute for Research on Aging, University of California San Diego UCSD filed Critical J David Gladstone Institutes
Publication of CA3070453A1 publication Critical patent/CA3070453A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3070453A 2017-07-21 2018-07-19 S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same Pending CA3070453A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535754P 2017-07-21 2017-07-21
US62/535,754 2017-07-21
PCT/US2018/042948 WO2019018683A1 (en) 2017-07-21 2018-07-19 BETA-HYDROXYBUTYRATE AND BUTANEDIOL ENANTIOMERS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
CA3070453A1 true CA3070453A1 (en) 2019-01-24

Family

ID=65015819

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3070453A Pending CA3070453A1 (en) 2017-07-21 2018-07-19 S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same

Country Status (11)

Country Link
US (1) US11773051B2 (https=)
EP (1) EP3654963A4 (https=)
JP (1) JP7442095B2 (https=)
KR (1) KR102795284B1 (https=)
CN (1) CN111050764A (https=)
AU (1) AU2018304380B2 (https=)
BR (1) BR112020001285A2 (https=)
CA (1) CA3070453A1 (https=)
IL (1) IL272173B2 (https=)
MX (1) MX2020000734A (https=)
WO (1) WO2019018683A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245243B1 (en) * 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
CN114292190B (zh) 2016-06-07 2025-04-11 J大卫格莱斯顿研究机构 丁二醇的中链脂肪酸酯，其组合物、口服制剂及其应用方法
MX2020000734A (es) 2017-07-21 2020-07-29 Buck Inst Res Aging Enantiómeros s de beta-hidroxibutirato y butanodiol, y métodos para usarlos.
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
JP7448555B2 (ja) * 2019-02-11 2024-03-12 アクセス・グローバル・サイエンシーズ・エルエルシー ラセミベータ－ヒドロキシブチレート混合塩－酸組成物および使用方法
WO2020167692A1 (en) * 2019-02-11 2020-08-20 Access Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the r-enantiomer and methods of use
CA3129751A1 (en) * 2019-02-11 2020-08-20 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with s-enantiomer
CN109806251A (zh) * 2019-03-04 2019-05-28 清华大学 3-羟基丁酸及其衍生物在制备抗动脉粥样硬化的产品中的应用
WO2020186154A1 (en) * 2019-03-14 2020-09-17 The Regents Of The University Of California Methods and compositions for supporting renal health
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
EP4146337B1 (de) * 2020-07-13 2024-04-17 KetoLipix Therapeutics GmbH Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren
WO2022012766A1 (de) * 2020-07-13 2022-01-20 Ioi Oleo Gmbh Verfahren zur herstellung von oxobutanol-estern von polymeren carbonsäuren
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN112341542B (zh) * 2021-01-08 2021-05-14 清华大学 一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用
US20220249497A1 (en) * 2021-02-05 2022-08-11 Health Via Modern Nutrition, Inc. Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance
EP4366720A4 (en) * 2021-07-09 2025-05-07 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
US20250282707A1 (en) * 2022-04-29 2025-09-11 Buck Institute For Research On Aging Novel ketone ester compounds
EP4566598A1 (en) * 2023-12-04 2025-06-11 ZoSaLa Pharma, Inc Compositions providing sglt2i and bhb activity and methods of use to treat human disease
WO2025166164A1 (en) 2024-02-02 2025-08-07 Selah Therapeutics Limited DL- AND L-β-HYDROXYBUTYRATE AND METHODS OF USE THEREOF

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS42663Y1 (https=) 1966-03-07 1967-01-17
US4263216A (en) 1978-10-20 1981-04-21 The Procter & Gamble Company Diglyceride manufacture
US4436726A (en) 1980-12-15 1984-03-13 Fujisawa Pharmaceutical Co., Ltd. N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions
BE1001209A3 (fr) 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
US5126373A (en) * 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
EP0633319B1 (en) 1988-04-27 1999-03-17 Daicel Chemical Industries, Ltd. Process for producing optically active 1,3-butanediol
JP2578658B2 (ja) 1989-02-21 1997-02-05 チッソ株式会社 光学活性化合物及びその製造法
US5008126A (en) 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
IT1240760B (it) 1990-02-12 1993-12-17 Sigma Tau Ind Farmaceuti Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma.
DE69205560T2 (de) 1992-01-08 1996-04-11 Nestle Sa Kosmetische und dermatologische Zusammensetzung, die Dioldiester enthält.
DE19703471A1 (de) 1997-01-31 1998-08-06 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Butylenglycoldiestern
CA2283642C (en) 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
DE60001686T2 (de) 1999-05-11 2003-08-21 Dow Agrosciences Llc, Indianapolis Verfahren zum Herstellen von substituierten 3-Hydroxybuttersäureester
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
CN101426763A (zh) 2000-10-11 2009-05-06 埃斯佩里安医疗公司 用于胆固醇治疗和相关应用的硫化物和二硫化物化合物和组合物
WO2004062604A2 (en) 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
EP1648952B1 (en) 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
EP1528053A1 (en) 2003-10-31 2005-05-04 Lonza Ag Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates
JP2006063001A (ja) 2004-08-25 2006-03-09 Takasago Internatl Corp 光学活性β−ブチロラクトンの製造方法
US7988883B2 (en) 2006-02-10 2011-08-02 Dupont Tate & Lyle Bio Products Company, Llc Heat transfer compositions comprising renewably-based biodegradable 1,3-propanediol
JP5054418B2 (ja) 2007-04-23 2012-10-24 ポーラ化成工業株式会社 クレンジング用の化粧料に好適な皮膚外用剤
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
EP3296284B1 (en) 2008-08-21 2021-12-01 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Non-therapeutical use of hydroxybutyrate ester
CA2760410A1 (en) * 2009-04-16 2010-10-21 Isis Innovation Limited Process for the preparation of (3r)-hydr0xybutyl (3r) -hydroxybutyrate by enzymatic enantioselective reduction employing lactobacillus brevis alcohol dehydrogenase
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
MX2012012390A (es) 2010-04-28 2012-11-30 Arkema Inc Metodo para mejorar la estabilidad de mezclas de polioles poliuretanicos que contienen un agente de soplado olefinico halogenado.
KR101243240B1 (ko) 2010-07-19 2013-04-04 (주)에이씨티 신규 알킬디올 유도체화합물 및 이를 포함하는 미백용 피부외용제조성물
CN103360243B (zh) 2012-03-31 2015-06-17 中国石油化工股份有限公司 一种1,3-二酰氧基丙烷类化合物的制备方法
KR101291441B1 (ko) 2012-05-01 2013-07-30 코니카 미놀타 어드밴스드 레이어즈 인코포레이티드 위상차 필름, 편광판의 제조 방법 및 액정 표시 장치
WO2014085652A1 (en) 2012-11-28 2014-06-05 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
SG11201507685UA (en) 2013-03-14 2015-10-29 Isis Innovation Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
KR102499654B1 (ko) 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
ES2734209T3 (es) 2013-08-06 2019-12-04 Imago Biosciences Inc Inhibidores de KDM1A para el tratamiento de enfermedades
WO2016123229A1 (en) * 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
US20180200220A1 (en) * 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
CN114292190B (zh) 2016-06-07 2025-04-11 J大卫格莱斯顿研究机构 丁二醇的中链脂肪酸酯，其组合物、口服制剂及其应用方法
MX2020000734A (es) 2017-07-21 2020-07-29 Buck Inst Res Aging Enantiómeros s de beta-hidroxibutirato y butanodiol, y métodos para usarlos.
WO2019147503A1 (en) * 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20190262415A1 (en) 2018-02-26 2019-08-29 Ketologie LLC Supplement for inducing and sustaining nutritional ketosis
WO2021211609A1 (en) 2020-04-16 2021-10-21 Buck Institute For Research On Aging Treatment of viral pathologies with exogenous ketones

Also Published As

Publication number Publication date
KR102795284B1 (ko) 2025-04-11
CN111050764A (zh) 2020-04-21
IL272173A (en) 2020-03-31
BR112020001285A2 (pt) 2020-07-28
IL272173B2 (en) 2025-06-01
JP7442095B2 (ja) 2024-03-04
IL272173B1 (en) 2025-02-01
MX2020000734A (es) 2020-07-29
US20200140371A1 (en) 2020-05-07
WO2019018683A1 (en) 2019-01-24
JP2020527583A (ja) 2020-09-10
KR20200029547A (ko) 2020-03-18
EP3654963A4 (en) 2021-04-14
EP3654963A1 (en) 2020-05-27
AU2018304380B2 (en) 2022-12-15
AU2018304380A1 (en) 2020-01-30
US11773051B2 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
AU2018304380B2 (en) S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
US20240317671A1 (en) Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20080009467A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
CN101842103A (zh) 用于脑部健康的单位剂量
US20220378731A1 (en) Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column
KR101734152B1 (ko) 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
WO2009005519A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US20240122890A1 (en) Use of exogenous ketone esters to induce weight loss in mammals
CA2576385C (en) Novel formulation for l-tryptophane comprising carbidopa/benserazide
US20250282707A1 (en) Novel ketone ester compounds
JP2021536494A (ja) マグネシウム含有製剤及びその使用
US20250161270A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
EP4665327A1 (en) Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with n-acylethanolamines, and uses thereof
WO2022140279A1 (en) Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230712

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240715

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250528

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250708

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250708

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250820

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260120

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260120

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: OFFER OF REMISSION

Effective date: 20260302

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260302